<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Heparin Induced Thrombocytopenia • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Heparin Induced Thrombocytopenia • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/heparin induced thrombocytopenia/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/heparin induced thrombocytopenia/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="heparin-induced-thrombocytopenia-and-thrombosis" tabindex="-1">heparin induced thrombocytopenia and thrombosis</h1>
<ul>
<li>related: <a href="/wiki/notes/Hemeonc/">Hemeonc</a></li>
</ul>
<h2 id="type-1-hitt" tabindex="-1">type 1 HITT</h2>
<ul>
<li>within 2 days of initiating heparin</li>
<li>transient, non pathologic</li>
<li>Plt &gt; 100k</li>
<li>Do not stop heparin, plt will return to normal</li>
</ul>
<h2 id="type-2-hitt" tabindex="-1">type 2 HITT</h2>
<ul>
<li>antibody against PF4 =&gt; activates Plt =&gt; plt cascades =&gt; thrombosis and thrombocytopenia</li>
<li>most often unfractionated heparin</li>
<li>CV surgery, ortho surgery</li>
<li>more or longer heparin =&gt; more likely to get HITT</li>
<li>patients with endothelial damage</li>
<li>clotting is worse than bleeding</li>
<li>arterial and venous clot</li>
<li>interpret based on 4T score
<ul>
<li>e.g. low 4T with positive test: 1% chance positive HITT</li>
</ul>
</li>
<li>Stop argatroban: when Plt &gt; 150k, then switch to DOAC or warfarin for minimum of 6 months</li>
</ul>
<h2 id="case" tabindex="-1">case</h2>
<p>This patient with likely <em>Escherichia coli</em> pyelonephritis has mild thrombocytopenia, prolonged INR/PTT, and low to normal fibrinogen, raising suspicion for disseminated intravascular coagulation (DIC).  On hospital day 2, her platelet count drops to 105,000/mm3; the likely etiologies include ongoing DIC, antibiotics (eg, ceftriaxone), or <strong>heparin-induced thrombocytopenia (HIT) type 1</strong>.</p>
<p>HIT type 1 is a mild thrombocytopenia caused by nonimmune-mediated platelet aggregation.  Nadirs of approximately 100,000/mm3 occur &lt;2 days after heparin initiation, and platelet counts return to normal <strong>without any alteration in management</strong>.</p>
<p>Conversely, HIT type 2 is life-threatening, requires aggressive treatment, and is characterized by the 4 Ts:</p>
<ul>
<li>Thrombocytopenia - platelets typically <strong>decline &gt;30%-50%</strong></li>
<li>Timing - onset <strong>5-10 days after heparin</strong> initiation or &lt;1 day with prior, recent heparin exposure</li>
<li>Thrombosis - new thrombosis, progressive thrombosis, or skin necrosis</li>
<li>Alternative causes - no other sources for thrombocytopenia are present or likely</li>
</ul>
<p>This patient has minimal evidence of HIT type 2; she would not require evaluation with platelet factor 4 (HIT) antibody or treatment with enoxaparin discontinuation and argatroban.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        <nav class="toc" >
        <ul><li><a href="#type-1-hitt">type 1 HITT</a></li><li><a href="#type-2-hitt">type 2 HITT</a></li><li><a href="#case">case</a></li></ul>
      </nav>
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Hemeonc/" class="peer">Hemeonc</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="hemeonc" tabindex="-1">Hemeonc</h1>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<ul>
<li><a href="/wiki/notes/management%20of%20bone%20metastasis/">management of bone metastasis</a></li>
<li><a href="/wiki/notes/Hematopoietic%20Stem%20Cells%20and%20Their%20Disorders/">Hematopoietic Stem Cells and Their Disorders</a></li>
<li><a href="/wiki/notes/Multiple%20Myeloma%20and%20Related%20Disorders/">Multiple Myeloma and Related Disorders</a></li>
<li><a href="/wiki/notes/Erythrocyte%20Disorders/">Erythrocyte Disorders</a></li>
<li><a href="/wiki/notes/Iron%20Overload%20Syndromes/">Iron Overload Syndromes</a></li>
<li><a href="/wiki/notes/Platelet%20Disorders/">Platelet Disorders</a></li>
<li><a href="/wiki/notes/MKSAP%20Bleeding%20Disorders/">MKSAP Bleeding Disorders</a></li>
<li><a href="/wiki/notes/MKSAP%20Transfusion%20Medicine/">MKSAP Transfusion Medicine</a></li>
<li><a href="/wiki/notes/Thrombotic%20Disorders/">Thrombotic Disorders</a></li>
<li><a href="/wiki/notes/Hematologic%20Issues%20in%20Pregnancy/">Hematologic Issues in Pregnancy</a></li>
<li><a href="/wiki/notes/Issues%20in%20Oncology/">Issues in Oncology</a></li>
<li><a href="/wiki/notes/Breast%20Cancer/">Breast Cancer</a></li>
<li><a href="/wiki/notes/Ovarian%20Cancer/">Ovarian Cancer</a></li>
<li>[[M</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
